Literature DB >> 3456282

Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors.

Y Matsumura, T Tsushima, Y Ozaki, J Yoshimoto, T Akagi, T Obama, Y Nasu, H Ohmori.   

Abstract

We evaluated the effects of 4'-epi-Adriamycin (EPI), a derivative of Adriamycin (ADR), in intravesical instillation chemotherapy. The patients received two courses of three daily instillations of 50-80 mg EPI dissolved in 30 ml physiological saline on 3 consecutive days, with an interval of 4 days between courses. Full evaluation was possible in 33 of 35 patients with superficial bladder tumors treated with EPI. Complete response was observed in 4 cases and partial response in 14 cases, giving a response rate of 55%. Side effects such as pollakiuria and pain on micturition occurred in 9 cases. EPI appears to be an effective agent for intravesical instillation chemotherapy in patients with superficial bladder tumors.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3456282     DOI： 10.1007/BF00256171

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  6 in total

1.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

2.  [Bladder instillation of adriamycin in the treatment of bladder tumors. Report 1: Clinical results (author's transl)].

Authors:  Y Ozaki
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1977-10

3.  Intravesical adriamycin chemotherapy in bladder cancer.

Authors:  Y Matsumura; Y Ozaki; H Ohmori
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Effect of 4'-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice.

Authors:  F C Giuliani; A K Coirin; M R Rice; N O Kaplan
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

Review 5.  4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.

Authors:  F Ganzina
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

6.  Toxic and therapeutic activity of 4'-epi-doxorubicin.

Authors:  V Bonfante; F Villani; G Bonadonna
Journal:  Tumori       Date:  1982-04-30
  6 in total
  11 in total

1.  Approaches to the treatment of bladder cancer at Stanford.

Authors:  F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory. Nara Uro-oncology Research Group. (NUORG).

Authors:  Y Hirao; S Ozono; H Momose; E Okajima; T Hiramatsu; K Yoshida; S Fukushima; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Superficial bladder cancer: state of the art.

Authors:  A V Bono
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.

Authors:  H Eto; Y Oka; K Ueno; I Nakamura; K Yoshimura; S Arakawa; S Kamidono; S Obe; T Ogawa; G Hamami
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.

Authors:  M D Melekos; I Zarakovitis; K Dandinis; E Fokaefs; H Chionis; H Dauaher; G Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 6.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice.

Authors:  Ainiwaer Aikemu; Nurmuhamat Amat; Abdiryim Yusup; Lianlian Shan; Xinwei Qi; Halmurat Upur
Journal:  Exp Ther Med       Date:  2016-05-10       Impact factor: 2.447

8.  Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.

Authors:  N Shinohara; K Nonomura; M Tanaka; S Nagamori; F Takakura; T Seki; T Koyanagi; M Togashi; A Maru
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Intravesical idarubicin--a phase-I study.

Authors:  W Schultze-Seemann; K Mross; K Burk; H Sommerkamp
Journal:  Urol Res       Date:  1994

10.  Intravesical chemotherapy.

Authors:  T Obama; Y Matsumura; H Ohmori
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.